Homburger advised Windward Bio, a private, clinical-stage biotechnology company, throughout completion of it USD 165 million series B Financing. In connection with the round, BG Partner represented lead investor OrbiMed, Novo Holdings, Blue Owl Capital and
Homburger advised Siegfried Holding in connection with the bridge financing for the acquisition of three drug substances sites in the US and Australia. The context On May 1, 2026, Siegfried Holding, a globally active Contract Development and
Homburger advised UBS AG and other dealers on the establishment of the Liechtensteiner Pfandbriefe Programme by Liechtensteinisches Pfandbriefinstitut AG, followed by an inaugural CHF 250 million bond issuance in April 2026.
Homburger advised the Joint Lead Managers on the issuance of EUR 500 million 3.925% Guaranteed Bonds by EFG International Finance (Luxembourg), guaranteed by EFG International AG and governed by Swiss law.
Homburger has advised UBS Switzerland AG in connection with Bachem Holding's new CHF 500 million revolving credit facility, with a team spanning financing and tax practices.
Homburger advises Mondelēz International, as the company placed bonds in Switzerland in the aggregate amount of CHF 850 m. The placement The CHF offering included CHF 325 m aggregate principal amount of 0.9575% senior notes due 2029, CHF 245
Homburger advised energy technology specialist Landis+Gyr on the divestment of its Europe, Middle East and Africa (EMEA) business to Aurelius, a globally active private equity investor. The transaction closed with economic effect on March 31, 2026.
Homburger advised UBS, PostFinance and Sygnum in connection with their joint CHF stablecoin sandbox. The new initiative — which also involved Raiffeisen, Zürcher Kantonalbank, BCV and Swiss Stablecoin —will test potential use cases for a
Niederer Kraft Frey (NKF) advised SHL Medical on its refinancing by a broad syndicate of lenders. In connection with the transaction, Homburger represented the syndicate itself, comprising of Bank of America, J.P. Morgan and
Marriott International and Italian luxury wellness hospitality specialist Lefay have signed binding agreements to enter a joint venture, bringing the Lefay brand into Marriott’s portfolio. The joint venture would entail an equal partnership aimed
